The upgraded CodeFusion Studio 2.0 simplifies how developers design, test and deploy AI on embedded systems.
Updated
January 8, 2026 6:34 PM
Illustration of CodeFusion Studio™ 2.0 showing AI, code and chip icons. PHOTO: ANALOG DEVICES, INC.
Analog Devices (ADI), a global semiconductor company, launched CodeFusion Studio™ 2.0 on November 3, 2025. The new version of its open-source development platform is designed to make it easier and faster for developers to build AI-powered embedded systems that run on ADI’s processors and microcontrollers.
“The next era of embedded intelligence requires removing friction from AI development”, said Rob Oshana, Senior Vice President of the Software and Digital Platforms group at ADI. “CodeFusion Studio 2.0 transforms the developer experience by unifying fragmented AI workflows into a seamless process, empowering developers to leverage the full potential of ADI's cutting-edge products with ease so they can focus on innovating and accelerating time to market”.
The upgraded platform introduces new tools for hardware abstraction, AI integration and automation. These help developers move more easily from early design to deployment.
CodeFusion Studio 2.0 enables complete AI workflows, allowing teams to use their own models and deploy them on everything from low-power edge devices to advanced digital signal processors (DSPs).
Built on Microsoft Visual Studio Code, the new CodeFusion Studio offers built-in checks for model compatibility, along with performance testing and optimization tools that help reduce development time. Building on these capabilities, a new modular framework based on Zephyr OS lets developers test and monitor how AI and machine learning models perform in real time. This gives clearer insight into how each part of a model behaves during operation and helps fine-tune performance across different hardware setups.
Additionally, the CodeFusion Studio System Planner has also been redesigned to handle more device types and complex, multi-core applications. With new built-in diagnostic and debugging features — like integrated memory analysis and visual error tracking — developers can now troubleshoot problems faster and keep their systems running more efficiently.
This launch marks a deeper pivot for ADI. Long known for high-precision analog chips and converters, the company is expanding its edge-AI and software capabilities to enable what it calls Physical Intelligence — systems that can perceive, reason, and act locally.
“Companies that deliver physically aware AI solutions are poised to transform industries and create new, industry-leading opportunities. That's why we're creating an ecosystem that enables developers to optimize, deploy and evaluate AI models seamlessly on ADI hardware, even without physical access to a board”, said Paul Golding, Vice President of Edge AI and Robotics at ADI. “CodeFusion Studio 2.0 is just one step we're taking to deliver Physical Intelligence to our customers, ultimately enabling them to create systems that perceive, reason and act locally, all within the constraints of real-world physics”.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.